Elicio Therapeutics FY Conference Summary Company Overview - **Company**: Elicio Therapeutics (NasdaqCM:ELTX) - **Industry**: Immunotherapy for cancer treatment - **Technology**: Amphiphile (AMP) platform developed at MIT, targeting lymph nodes for immunotherapy delivery [1][2] Core Points and Arguments Product Development - **Lead Program**: ELI-002, targeting mutated KRAS, currently in phase 2 trials for gastrointestinal (GI) cancers, specifically pancreas and colorectal cancers [2][3] - **Clinical Trials**: - Phase 1 trials showed robust T-cell responses, expanding up to 44 times baseline levels [4][5] - Phase 2 trial expected to provide final analysis of primary endpoint in the first half of 2026 [3][34] Market Opportunity - **KRAS Mutation**: Present in approximately 25% of human solid cancers, with 90% of pancreas cancer cases having KRAS mutations [13][14] - **Potential Patient Population**: Targeting patients with MRD positive status, who have a poor prognosis with standard observation leading to median relapse-free survival of 5-12 months [20] Clinical Efficacy - **Survival Rates**: - Median relapse-free survival in phase 1 trials was 16.33 months, threefold longer than historical data for MRD positive pancreas cancer [21] - Median overall survival increased from 16.33 to 28.94 months in final analysis [21] - **T-cell Response Correlation**: Strong correlation between T-cell responses and clinical benefits, with an 88% reduced risk of relapse for patients with above-threshold T-cell responses [22] Technology Differentiation - **Mechanism of Action**: Utilizes albumin to enhance lymph node targeting, improving immune response against tumors [11][12] - **Antigen Spreading**: Observed phenomenon where immune response extends beyond KRAS to other tumor-associated antigens, indicating a personalized immune response [26][33] Additional Important Information - **Pipeline Expansion**: Future opportunities include targeting BRAF and P53 mutations, with ongoing discussions for investigator-sponsored trials [34] - **Regulatory Interactions**: Productive discussions with the FDA regarding phase 3 trial design, focusing on randomized blinded trials with DFS as the primary endpoint [30][34] - **Financial Overview**: As of September 30, 2025, financial details were briefly mentioned, indicating ongoing resource allocation for development [34] This summary encapsulates the key points from the Elicio Therapeutics FY Conference, highlighting the company's innovative approach to cancer immunotherapy, the promising clinical results of its lead product, and the significant market opportunity presented by KRAS mutations.

Core Insights - Elicio Therapeutics has reported promising results from the Phase 2 AMPLIFY-7P trial, indicating that ELI-002 7P can induce antigen spreading in a majority of patients, enhancing immune responses against non-mKRAS neoantigens [1][5] Company Overview - Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment, particularly targeting high-prevalence cancers like mKRAS-positive pancreatic and colorectal cancers [6] - The company utilizes its proprietary Amphiphile (AMP) technology to enhance the activation and amplification of cancer-specific T cells, aiming for durable cancer immunosurveillance [6][9] Clinical Trial Results - In the ongoing Phase 2 AMPLIFY-7P trial, 87% (13 out of 15) of evaluated patients exhibited significant T cell responses to non-mKRAS tumor neoantigens, indicating a broadening of the immune response beyond the targeted antigens [3][5] - The median fold change in T cell response over baseline for the Phase 2 trial was reported at 10.6x, demonstrating a robust immune response [3] - The trial included 90 evaluable patients, with 15 selected for antigen spreading analysis based on sufficient blood samples and tumor sequencing data [3] Product Candidate Details - ELI-002 is an off-the-shelf immunotherapy candidate targeting common KRAS mutations, which are implicated in approximately 25% of all solid tumors [6][7] - The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations, thereby increasing the potential patient population [8] Future Directions - Elicio plans to expand the application of ELI-002 to other indications, including mKRAS-positive lung cancer and other mKRAS-positive cancers, building on the clinical successes in personalized cancer immunotherapy [6][12]